X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    DAWNZERA for Hereditary Angioedema

    U.S. FDA Approves Ionis’ DAWNZERA for Hereditary Angioedema

    Major Depressive Disorder

    AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

    FDA Approved Papzimeos

    The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

    Biosimilar Ranibizumab

    Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    Thermo Fisher New HMW Kit Powers Long Read DNA Sequencing

    Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Agentic AI in Pharma Transforming RD to Commercialisation

    Agentic AI in Pharma: Transforming R&D to Commercialisation

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    DAWNZERA for Hereditary Angioedema

    U.S. FDA Approves Ionis’ DAWNZERA for Hereditary Angioedema

    Major Depressive Disorder

    AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

    FDA Approved Papzimeos

    The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

    Biosimilar Ranibizumab

    Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brinsupri by Insmed for Chronic Lung Condition

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    FDA Approves Brain Tumour Treatment Modeyso by Jazz Pharma

    Thermo Fisher New HMW Kit Powers Long Read DNA Sequencing

    Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Taiwan Grants Full Approval for NEFECON IgAN Treatment

    Agentic AI in Pharma Transforming RD to Commercialisation

    Agentic AI in Pharma: Transforming R&D to Commercialisation

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

U.S. FDA Approves Ionis’ DAWNZERA for Hereditary Angioedema

API PA by API PA
28th August 2025
in FDA Approvals, News
DAWNZERA for Hereditary Angioedema

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted approval for DAWNZERA™ (donidalorsen). The treatment is approved for prophylaxis to avoid hereditary angioedema (HAE) attacks in pediatric and adult patients aged 12 years and older. DAWNZERA is the first RNA-targeting therapy approved for use in this condition. The treatment works by targeting plasma prekallikrein (PKK), a protein involved in the activation of inflammatory mediators associated with acute HAE attacks. DAWNZERA 80mg can be self-administered subcutaneously using an autoinjector once every four weeks (Q4W) or every eight weeks (Q8W).

HAE is a rare but potentially fatal genetic condition that involves repeated episodes of severe swelling, or angioedema, that can occur in the hands, feet, stomach, face, throat or genitals. In the U.S., an estimated 7,000 people suffer from this disease.

“DAWNZERA represents a significant advance for people living with HAE who need improved treatment options. With strong and durable efficacy, convenient administration and the longest dosing option available, we believe DAWNZERA will be the prophylactic treatment of choice for many people living with HAE. Importantly, the recently published switch data empowers patients and physicians with a roadmap for switching to DAWNZERA from other prophylactic therapies,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “At Ionis, we are dedicated to turning groundbreaking science into life-changing medicines. With the early success of our first independent launch of TRYNGOLZA® for familial chylomicronemia syndrome (FCS), and now with DAWNZERA, our second independent medicine approved in less than nine months, we are proudly delivering on that vision. To the patients, families, advocacy partners and investigators who helped make this moment a reality, we express our deepest gratitude.”

The FDA’s approval was supported by results from the Phase 3 OASIS-HAE study, a global, multicenter, randomized, double-blind, placebo-controlled study. This study achieved its primary endpoint, with DAWNZERA Q4W reducing monthly attack rates by 81% over 24 weeks compared to placebo. Second dose achieved its endpoint with an 87% mean attack rate reduction. Also, moderate-to-severe HAE attacks decreased by almost 90% over 24 weeks after the second dose. 

These results were supported by the OASISplus open-label extension trial. In this trial, DAWNZERA Q8W showed similar efficacy as the Q4W over time. After a year, both groups of patients had a 94% reduction in mean baseline attack rates.

The OASISplus trial also included a switch cohort that studied patients who had already been treated with other treatments like lanadelumab, C1-esterase inhibitor or berotralstat for at least 12 weeks. Transitioning to DAWNZERA for Hereditary Angioedema patients led to a 62% reduction in mean HAE attack rates compared with other prophylactic treatments over 16 weeks. No increase in breakthrough attacks was observed during the switch period. 84% of surveyed patients indicated they preferred DAWNZERA for Hereditary Angioedema over earlier options due to improved disease control, faster administration, and less discomfort at the injection site.

Across multiple clinical studies, DAWNZERA demonstrated a favorable safety and tolerability profile. The most common adverse reactions, reported in at least 5% of patients, included mild injection site reactions, upper respiratory tract infections, urinary tract infections and abdominal discomfort.

“As the first FDA-approved RNA-targeted therapy for HAE, DAWNZERA represents a welcome advance in therapeutic options for preventing attacks. Today’s approval gives people living with HAE and their physicians another important choice for aligning treatment with individual needs,” said Anthony J. Castaldo, CEO & chairman of the board, U.S. Hereditary Angioedema Association (HAEA) and Hereditary Angioedema International (HAEi).

“People living with HAE manage this condition for all their lives, and many continue to face unpredictable, painful and dangerous breakthrough attacks even with current treatments. Durable efficacy is essential in maintaining long-term disease control,” said Marc Riedl, M.D., M.S., clinical director, U.S. HAEA Angioedema Center; University of California, San Diego; OASIS-HAE and OASISplus trial investigator. “DAWNZERA is positioned to help meet patient needs, providing substantial and sustained reduction of HAE attacks, continued improvement over time and reduced burden of treatment.”

DAWNZERA will be available in the U.S. in the coming days.

Tags: DosesFDA
Previous Post

Roche's Genentech Launches New Manufacturing Facility in USA

Related Posts

Manufacturing Facility in USA
Americas

Roche’s Genentech Launches New Manufacturing Facility in USA

28th August 2025
JJ Investment
Americas

J&J Investment of $2B Boosts US Drug Manufacturing Capacity

26th August 2025
Pharmaceutical Tariff
Americas

Pharmaceutical Tariff Agreed at 15% Under US-EU Trade Deal

26th August 2025
FDA Approved Papzimeos
Americas

The U.S. FDA Approved Papzimeos for RRP Treatment in Adults

25th August 2025
US Pharma Supply Chain
Americas

Trump Signs Executive Order to Boost US Pharma Supply Chain

20th August 2025
Biosimilar Ranibizumab
Asia

Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

18th August 2025

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In